Showing 5191-5200 of 6964 results for "".
- Expert FDA Panel Recommends Skin Lesion Analyzers and Apps for Skin Cancer Detection Keep Class III Statushttps://practicaldermatology.com/news/expert-fda-panel-recommends-skin-lesion-analyzers-and-apps-for-skin-cancer-detection-keep-class-iii-status/2461293/The FDA held a meeting with the Medical Devices Advisory Committee in late July to gather expert advice on the regulation of AI driven, skin lesion analyzers (SLAs) and Apps for skin cancer detection. Panel members urged caution for skin cancer detection SLAs and Apps and stressed the need for mo
- Arcutis Completes Enrollment in Pivotal Phase 3 Roflumilast AD Trialhttps://practicaldermatology.com/news/arcutis-completes-enrollment-in-pivotal-phase-3-roflumilast-ad-trial/2461290/Arcutis Biotherapeutics, Inc. has completed enrollment of the last subject in its INTEGUMENT-1 pivotal Phase 3 trial of roflumilast cream 0.15% in adults and children with atopic dermatitis (AD). Roflumilast cream is a once daily topical formulation of roflumilast, a highly potent and s
- First Patient Enrolled in UNION Therapeutic’s Study of Orismilast MR tablet in ADhttps://practicaldermatology.com/news/first-patient-enrolled-in-union-therapeutics-study-of-orismilast-mr-tablet-in-ad/2461288/The first patient has been enrolled in ADESOS, a Phase 2b dose-finding study evaluating the safety and efficacy of UNION therapeutic’s orismilast MR tablet in adult patients with moderate to severe AD. The purpose of the study is to identify the appropria
- FDA Approves JUVÉDERM VOLUX XC for Jawline Definitionhttps://practicaldermatology.com/news/fda-approved-juvederm-volux-xc-for-jawline-definition/2461286/The U.S. FDA has given its nod to JUVÉDERM VOLUX XC for the improvement of jawline definition in adults over the age of 21 with moderate to severe loss of jawline definition. "The approval of JUVÉDERM VOLUX XC represents the largest leap in innovation for ou
- NRS Survey: Persistent Facial Redness Named Most Common and Bothersome Sign of Rosaceahttps://practicaldermatology.com/news/nrs-survey-persistent-facial-redness-is-the-most-common-and-bothersome-sign-of-rosacea/2461285/The great majority of rosacea patients have experienced persistent facial redness, and most of them report it is the most frequently bothersome sign they face, according to a recent National Rosacea Society (NRS) survey on rosacea redness sponsored by EPI Health. Furthermore, two-
- FDA Nod for Stelara in Pediatric Psoriatic Arthritishttps://practicaldermatology.com/news/fda-nod-for-stelara-in-pediatric-psoriatic-arthritis/2461284/The FDA approved Stelara (ustekinumab) for the treatment of pediatric patients six years of age and older with active psoriatic arthritis (PsA). Stelara is a fully human monoclonal antibody that selectively inhibits both interleukin (IL)-12 and IL-23, two cytokines thought to
- CeraVe, Top Derms, and Skincare Enthusiasts Partner to Teach Consumers to #CleanseLikeaDermhttps://practicaldermatology.com/news/cerave-top-derms-and-skincare-enthusiasts-partner-to-teach-consumers-to-cleanselikeaderm/2461283/CeraVe is teaming up with board-certified dermatologists and two of the biggest dermatologist influencers on social media today – Dr. Dustin Portela (@208skindoc) and Dr. Michelle Henry (@drmichellehenry) – to host a global livestreamed event with skincare enthusiast and content creat
- Zoryve from Arcutis Approved for Plaque Psoriasishttps://practicaldermatology.com/news/zoryve-from-arcutis-approved-for-plaque-psoriasis/2461282/FDA has approved the New Drug Application (NDA) for Zoryve (roflumilast) cream 0.3% from Arcutis Biotherapeutics for the treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age or older. The first and only topical phosphodiesterase-4 (PDE4) inhib
- The Foundation for Research and Education in Dermatology Welcomes Matt L. Leavitt, DO to Boardhttps://practicaldermatology.com/news/the-foundation-for-research-and-education-in-dermatology-welcomes-matt-l-leavitt-do-to-board/2461281/The Foundation for Research and Education in Dermatology (FRED), has named Matt L. Leavitt, DO as new member of its board. The Foundation says this decision marks the latest step in expanding its leadership at the executive and advisory levels. Dr. Leavitt is a board-certified derm
- Aesthetics Biomedical Adds to Leadership Team to Fuel Growth Trajectoryhttps://practicaldermatology.com/news/aesthetics-biomedical-adds-to-leadership-team-to-fuel-growth-trajectory/2461280/In an ongoing efforts to meet the increasing demand for its aesthetic products and distribution growth, Aesthetics Biomedical Inc. (ABM), is continuing to build its executive team with the recent hires of industry experts Derek Harmon as Vice President of U.S. Sales and Don Selvey, NMD, MS as Vic